Report: China's Hengrui licenses weight-loss drug to Denmark's Novo Nordisk in deal worth up to $2.6B

Anadolu Agency (Turkey) has reported on “Report: China's Hengrui licenses weight-loss drug to Denmark's Novo Nordisk in deal worth up to $2.6B,” presenting it as the central development in the source material available for this brief.

The available account reports that experimental once-weekly oral drug designed to reduce weight, improve blood sugar control

Any statements, estimates or characterisations remain attributed to the people or organisations identified by the source. The excerpt alone does not provide a complete documentary record or necessarily include responses from every party involved.

Official statements or subsequent reporting may add context as the story develops. For now, this account is confined to information directly supported by the provided headline and excerpt.